Clinical Effect Analysis of Obstructive Sleep Apnea Hypopnea Syndrome

Objective: To compare the effect of combined nasal continuous positive airway pressure respiration combined with drugs on obstructive sleep apnea-hypopnea syndrome (OSAHS) in different conditions to further evaluate the clinical effect of OSAHS. 82 patients with OSAHS admitted to our hospital from January 2016 to December 2019 are selected and divided into 2 groups according to the severity of OSAHS disease. 52 patients with moderate OSAHS and 30 patients with severe OSAHS are treated with nasal-continuous positive airway pressure (CPAP) combined with pedomodorus and Monrothna. The sleep quality is evaluated before treatment and 3 months after treatment, and the average blood oxygen saturation at night and the longest hypopnea time is determined. Results show thatthe Pittsburgh sleep index score of patients in the severe OSAHS group before treatment is lower than that in the moderate OSAHS group, and the average blood oxygen saturation level at night is higher than that in the moderate OSAHS group. The longest hypoventilation time is shorter than that in the OSAHS group. The difference is statistically significant (P <0.05); after 3 months of treatment, this index is improved in both groups, and Pittsburgh sleep index score, mean nighttime blood oxygen saturation level and time difference of longest hypoventilation are significantly higher in the moderate OSAHS group before and after 3 months of treatment than in the severe OSAHS group, with statistically significant differences (P<0.05). Therefore, the treatment of OSAHS patients with CPAPcombined with Peidomod and Monrothna can effectively improve the sleep quality, increase the mean oxygen saturation at night, and reduce the duration of hypoventilation. However, it should be implemented as soon as possible to improve the clinical effect.